Answers are grounded in this paper and cite their sources.
Oncogenic MYC amplification drives glutamine addiction in hepatocellular carcinoma (HCC), rendering glutaminase (GLS) a promising therapeutic target. However, MYC-amplified HCC frequently exhibits intrinsic resistance to the GLS inhibitor CB-839, with the underlying adaptive survival mechanisms remaining elusive. Here, we demonstrate that MYC-high HCC cells critically depend on mitofusin 1 (MFN1)-mediated mitochondrial fusion to maintain survival under glutaminolysis inhibition. Furthermore, we show that glutaminolysis inhibition enhances the stability of CCAAT/enhancer-binding protein β (C/EBPβ), which directly activates MFN1 transcription. Mechanistically, MYC-dependent transactivation of FAM63A mediates the deubiquitination of C/EBPβ, specifically suppressing its K48-linked polyubiquitination to enhance C/EBPβ protein stability under glutamine deprivation. Importantly, inhibition of C/EBPβ abrogates MFN1-mediated mitochondrial fusion and triggers autophagic cell death, thereby sensitizing MYC-high HCC cells to GLS inhibition. Our findings identify a novel MYC-FAM63A-C/EBPβ-MFN1 signaling axis that confers adaptive resistance to GLS inhibitors in MYC-high HCC by sustaining mitochondrial fusion. Thus, targeting C/EBPβ represents a promising combinatorial therapeutic strategy to overcome CB-839 resistance in this clinically challenging HCC subtype.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: